3 results
To evaluate the efficacy of tofacitinib treatment in patients with RCDII with persistent or recurrent villous atrophy (Marsh III ABC) and aberrant IEL T-cells (> 20% as assessed by flow cytometry).
The objective of this study is three-fold: 1) Assess measurement settings and develop the data processing chain to detect contrast signals in the left-ventricular wall with contrast-enhanced high-frame rate echocardiography. Determine whether this…
Primary objective:Identify pre-treatment profiles with integrated clinical, transcriptomic, metabolomic, proteomic, flow cytometric, and imaging data that predict response to treatment with tofacitinib, in DMARD-naïve and DMARD non-responsive PsA…